Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC Meeting Abstract
| Authors: | Burris, H. A.; Callahan, M. K.; Tolcher, A. W.; Kummar, S.; Falchook, G. S.; Pachynski, R. K.; Tykodi, S. S.; Gibney, G. T.; Seiwert, T. Y.; Gainor, J. F.; LoRusso, P.; Hilbert, J.; Apgar, J. F.; Hua, F.; Burke, J. M.; Lazard, M.; Clancy, M.; Ding, B.; Trehu, E. G.; Yap, T. A. |
| Abstract Title: | Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 146s |
| Language: | English |
| ACCESSION: | WOS:000411895705163 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.3033 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3033 -- Source: Wos |
